Matches in Wikidata for { <http://www.wikidata.org/entity/Q61628279> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- Q61628279 description "article" @default.
- Q61628279 description "im März 2015 veröffentlichter wissenschaftlicher Artikel" @default.
- Q61628279 description "wetenschappelijk artikel" @default.
- Q61628279 description "наукова стаття, опублікована в березні 2015" @default.
- Q61628279 name "Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study" @default.
- Q61628279 name "Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study" @default.
- Q61628279 type Item @default.
- Q61628279 label "Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study" @default.
- Q61628279 label "Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study" @default.
- Q61628279 prefLabel "Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study" @default.
- Q61628279 prefLabel "Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study" @default.
- Q61628279 P1433 Q61628279-877E51B4-4E1A-41FE-A11F-DE0058907A26 @default.
- Q61628279 P1476 Q61628279-D8D473D6-47AA-4F73-BCBA-08F083FA40CA @default.
- Q61628279 P2093 Q61628279-517FFAA9-4B28-4388-A1CA-615776ECDDD6 @default.
- Q61628279 P2093 Q61628279-70F93B5E-458C-4941-A8AF-501F9CB782B8 @default.
- Q61628279 P2093 Q61628279-B5CFE307-BD5D-42E7-B516-7A5532AAB503 @default.
- Q61628279 P2093 Q61628279-D60D8FA2-26DD-441B-98C2-AD825A5C2802 @default.
- Q61628279 P2093 Q61628279-EBF7777E-80FB-450A-B63D-6D38465799B2 @default.
- Q61628279 P2093 Q61628279-F2D4CE25-0534-4984-B863-4AF7BD4FD8C6 @default.
- Q61628279 P304 Q61628279-7BAA79E6-4B04-4B11-A6D7-BD839E31B9D3 @default.
- Q61628279 P31 Q61628279-FACD33A8-0660-4F0B-A092-3F0C5A92DB60 @default.
- Q61628279 P356 Q61628279-A445C492-4948-472B-B81C-CF342BBDB2FB @default.
- Q61628279 P433 Q61628279-8729AC4D-003F-47D8-B541-561C2255CA25 @default.
- Q61628279 P478 Q61628279-6D344930-CED4-423E-877E-D391808B5D33 @default.
- Q61628279 P50 Q61628279-23312424-B00C-4E38-AE08-50DCD28C3B52 @default.
- Q61628279 P50 Q61628279-52363635-B6E2-4FB6-8CC3-B5F107F01E9A @default.
- Q61628279 P50 Q61628279-7A44B77E-7833-4D29-AD65-2755F0600DDB @default.
- Q61628279 P50 Q61628279-87FB1B1F-26BE-483A-A458-644233FF44F9 @default.
- Q61628279 P50 Q61628279-CE726A44-0E88-4B45-8D75-595E66190917 @default.
- Q61628279 P50 Q61628279-CEFE021B-F1ED-4246-B52F-28784DA5E92F @default.
- Q61628279 P577 Q61628279-3F01569F-17AA-4044-BEDB-06DA1B4216D3 @default.
- Q61628279 P698 Q61628279-02394F91-4D28-43DC-A0A5-614F7388E57C @default.
- Q61628279 P921 Q61628279-16ECEC2D-7D81-49F3-B2E3-9B93B05E8B8C @default.
- Q61628279 P921 Q61628279-2836888D-DF28-4F0A-8E26-8858D01A7BF5 @default.
- Q61628279 P921 Q61628279-3376C6E5-4531-47E5-9090-5C16E2DC2D93 @default.
- Q61628279 P921 Q61628279-49AC81D4-E7E4-407E-8899-F12235CE95BB @default.
- Q61628279 P921 Q61628279-D2E3EE71-8A83-4386-97EB-6D8F04C0327A @default.
- Q61628279 P921 Q61628279-D336EFFB-A13C-4F0C-97F8-DB7550BAD8BF @default.
- Q61628279 P921 Q61628279-E20EE04B-4D35-434A-AE54-007B91B0681F @default.
- Q61628279 P356 J.EJCA.2014.12.020 @default.
- Q61628279 P698 25637137 @default.
- Q61628279 P1433 Q332260 @default.
- Q61628279 P1476 "Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study" @default.
- Q61628279 P2093 "Alessandro Bertolini" @default.
- Q61628279 P2093 "Andrea Ciarlo" @default.
- Q61628279 P2093 "Claudio Verusio" @default.
- Q61628279 P2093 "Emilio Bajetta" @default.
- Q61628279 P2093 "Enrico Aitini" @default.
- Q61628279 P2093 "Sandro Barni" @default.
- Q61628279 P304 "473-481" @default.
- Q61628279 P31 Q13442814 @default.
- Q61628279 P356 "10.1016/J.EJCA.2014.12.020" @default.
- Q61628279 P433 "4" @default.
- Q61628279 P478 "51" @default.
- Q61628279 P50 Q37838216 @default.
- Q61628279 P50 Q37838236 @default.
- Q61628279 P50 Q40407083 @default.
- Q61628279 P50 Q42617207 @default.
- Q61628279 P50 Q55965774 @default.
- Q61628279 P50 Q57047350 @default.
- Q61628279 P577 "2015-01-27T00:00:00Z" @default.
- Q61628279 P698 "25637137" @default.
- Q61628279 P921 Q188874 @default.
- Q61628279 P921 Q412197 @default.
- Q61628279 P921 Q413299 @default.
- Q61628279 P921 Q420207 @default.
- Q61628279 P921 Q422327 @default.
- Q61628279 P921 Q42824440 @default.
- Q61628279 P921 Q6050805 @default.